Title : Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

Pub. Date : 2014 Mar 4

PMID : 24407191






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Irinotecan KRAS proto-oncogene, GTPase Homo sapiens